In August 2012, the DHVI was awarded a grant by the Bill & Melinda Gates Foundation to establish a Protein Production Facility, which is directed by James Peacock, PhD with oversight from Matthew Johnson, PhD (Associate Director of the Duke Human Vaccine Institute, and senior Director of Product Development).
The facility is equipped to produce and purify, at cost via subcontract, HIV-1 Env proteins and antibodies as standardized in vitro reagents which can be used in HIV vaccine research. These reagents are intended to optimize clinical trial immune monitoring and facilitate Env immunogen discovery; however, the proteins are not intended for use in humans or in clinical trials. The production of all proteins and antibodies is governed by a Quality Management plan with oversight by the Quality Assurance for Duke Vaccine Immunogenicity Program (QADVIP), Duke’s Quality Assurance Unit. All proteins and antibodies are produced following Standard Operating Procedures (SOPs) and using Good Documentation Practices. Environmental monitoring of the laboratory space, freezers, refrigerators and incubators is maintained and recorded in compliance with PPF SOPs.
If you are interested in collaborating with the Protein Production Facility, please contact:
Jamie Peacock, PhD
Protein Production Facility Manager
Cynthia Nagle, PhD